Skip to main content
SpringerLink
Log in

Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Introduction

In renal transplant patients, bone loss may be related to the drugs patients are taking but also to their past history of chronic kidney disease. The purpose of this study was to assess changes in BMD 2 years after an initial assessment (performed 9 months post transplantation) and the factors associated with these changes.

Methods

This longitudinal study included patients who had undergone a renal transplantation between 2005 and 2011, and who were followed up at the Lille Regional University Hospital. Patients were included if they had a first bone evaluation (including bone densitometry, spine X-rays and biological assessment) and at least another BMD assessment. The first assessment was performed on average 9 months post transplantation. A second assessment was performed at 2 years.

Results

Two hundred fifty-nine out of 366 patients satisfied the inclusion criteria. The population included 96 women. Mean age at transplantation was 49.7 ± 12.1 years. Mean duration of dialysis was 3.2 ± 3.3 years. For 75 patients (29.0%), corticosteroid treatment was discontinued 7 days after transplantation without subsequent resumption during follow-up. Vertebral fractures assessed by X-rays at baseline were found in 28 patients (10.8%). According to the WHO classification, 106 patients (40.9%) patients had osteoporosis and 111 patients (42.8%) had osteopenia at the first assessment. Oral bisphosphonates were prescribed for 95 patients. The decision to prescribe bisphosphonates was taken jointly by rheumatologists and nephrologists based on BMD assessment, past history of fracture and corticosteroid management. In all patients, BMD gains at the second evaluation (2.2 ± 0.79 years) compared with baseline were significant (3.9 ± 6.6, 2.6% ± 7.6, 3.0 ± 7.2% at the lumbar spine, femoral neck and total hip respectively; p < 0.0001). The difference in gain between bisphosphonate-treated and untreated patients was significant (+ 5.0 ± 0.8% (p < 0.0001), + 2.5 ± 1.0% (p = 0.01) and + 2.7 ± 0.9% (p < 0.01) at the lumbar spine, femoral neck and total hip respectively. The patients who benefited early corticosteroid discontinuation had higher gains in BMD at the lumbar spine (+ 2.1 ± 0.9%; p = 0.02) and total hip (+ 2.0 ± 1.0%; p = 0.04) compared to those for whom corticosteroid therapy was maintained. Stepwise regression analysis (patients without bisphosphonates) showed associations between change in BMD (femoral neck) and duration of corticosteroid therapy, bone alkaline phosphatase level at baseline, and absence of vertebral fracture. No correlation was found between change in BMD and duration of dialysis or renal function.

Conclusion

Kidney transplant recipients have an increased risk of bone fragility in the year following transplantation. Bisphosphonates and early corticosteroid discontinuation can improve BMD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Couchoud C (2015) REIN Annual Rapport 2013

  2. Eckardt K-U, Kasiske BL (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76:S1–S2. https://doi.org/10.1038/ki.2009.188

    Article  Google Scholar 

  3. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2008) Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 23:586–593. https://doi.org/10.1093/ndt/gfm660

    Article  PubMed  Google Scholar 

  4. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM (2006) PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47:149–156. https://doi.org/10.1053/j.ajkd.2005.09.024

    Article  PubMed  Google Scholar 

  5. Coco M, Rush H (2000) Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis Off J Natl Kidney Found 36:1115–1121. https://doi.org/10.1053/ajkd.2000.19812

    Article  CAS  Google Scholar 

  6. Mittalhenkle A, Gillen DL, Stehman-Breen CO (2004) Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 44:672–679. https://doi.org/10.1053/j.ajkd.2004.07.001

    Article  PubMed  Google Scholar 

  7. Kaneko TM, Foley RN, Gilbertson DT, Collins AJ (2007) Clinical epidemiology of long-bone fractures in patients receiving hemodialysis. Clin Orthop Relat Res 457:188–193. https://doi.org/10.1097/BLO.0b013e318031465b

    PubMed  Google Scholar 

  8. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD (1991) Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544–550. https://doi.org/10.1056/NEJM199108223250804

    Article  CAS  PubMed  Google Scholar 

  9. Rojas E, Carlini RG, Clesca P, Arminio A, Suniaga O, de Elguezabal K, Weisinger JR, Hruska KA, Bellorin-Font E (2003) The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 63:1915–1923. https://doi.org/10.1046/j.1523-1755.2003.00938.x

    Article  PubMed  Google Scholar 

  10. Nikkel LE, Hollenbeak CS, Fox EJ et al (2009) Risk of fractures after renal transplantation in the United States. [Miscellaneous Article]. Transplant 87:1846–1851. https://doi.org/10.1097/TP.0b013e3181a6bbda

    Article  Google Scholar 

  11. Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H (2003) Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14:2669–2676. https://doi.org/10.1097/01.ASN.0000087092.53894.80

    Article  CAS  PubMed  Google Scholar 

  12. Grotz WH, Mundinger FA, Rasenack J et al (1995) Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—ur Ren Assoc 10:2096–2100

    CAS  Google Scholar 

  13. Giannini S, D’Angelo A, Carraro G et al (2001) Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 16:2111–2117. https://doi.org/10.1359/jbmr.2001.16.11.2111

    Article  CAS  PubMed  Google Scholar 

  14. Horber FF, Casez JP, Steiger U et al (1994) Changes in bone mass early after kidney transplantation. J Bone Miner Res 9:1–9. https://doi.org/10.1002/jbmr.5650090102

    Article  CAS  PubMed  Google Scholar 

  15. Gupta AK, Huang M, Prasad GVR (2012) Determinants of bone mineral density in stable kidney transplant recipients. J Nephrol 25:373–383. https://doi.org/10.5301/jn.5000015

    Article  CAS  PubMed  Google Scholar 

  16. Jha V, Govindarajan S, Khandelwal N, Sakhuja V (2011) Bone mineral density in patients with end-stage renal disease and its evolution after kidney transplantation. Indian J Nephrol 21:85–89. https://doi.org/10.4103/0971-4065.82140

    Article  PubMed  PubMed Central  Google Scholar 

  17. Alshayeb HM, Josephson MA, Sprague SM (2013) CKD–mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis 61:310–325. https://doi.org/10.1053/j.ajkd.2012.07.022

    Article  CAS  PubMed  Google Scholar 

  18. Unal A, Kocyigit I, Sipahioglu MH, Tokgoz B, Kavuncuoglu F, Oymak O, Utas C (2010) Loss of bone mineral density in renal transplantation recipients. Transplant Proc 42:3550–3553. https://doi.org/10.1016/j.transproceed.2010.07.106

    Article  CAS  PubMed  Google Scholar 

  19. Nishioka S, Sofue T, Inui M, Nishijima Y, Moriwaki K, Hara T, Mashiba T, Kakehi Y, Kohno M (2014) Mineral and bone disorder is temporary in patients treated with early rapid corticosteroid reduction after kidney transplantation: a single-center experience. Transplant Proc 46:514–520. https://doi.org/10.1016/j.transproceed.2013.11.153

    Article  CAS  PubMed  Google Scholar 

  20. Nikkel LE, Mohan S, Zhang A, McMahon DJ, Boutroy S, Dube G, Tanriover B, Cohen D, Ratner L, Hollenbeak CS, Leonard MB, Shane E, Nickolas TL (2012) Reduced fracture risk with early corticosteroid withdrawal after kidney transplant: fewer fractures with ECSW after transplant. Am J Transplant 12:649–659. https://doi.org/10.1111/j.1600-6143.2011.03872.x

    Article  CAS  PubMed  Google Scholar 

  21. Long-term fracture risk following renal transplantation: a population-based study. Springer. https://doi.org/10.1007/s00198-003-1532-y

  22. Orcel P (2005) Prevention and treatment of glucocorticoid-induced osteoporosis in 2005. Joint Bone Spine 72:461–465. https://doi.org/10.1016/j.jbspin.2005.09.002

    Article  PubMed  Google Scholar 

  23. Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC (2001) Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12:1530–1537

    CAS  PubMed  Google Scholar 

  24. Jeffery JR, Leslie WD, Karpinski ME et al (2003) Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. [Miscellaneous Article]. Transplant 76:1498–1502

    Article  Google Scholar 

  25. Fan SL-S, Kumar S, Cunningham J (2003) Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int 63:2275–2279. https://doi.org/10.1046/j.1523-1755.2003.00012.x

    Article  CAS  PubMed  Google Scholar 

  26. El-Agroudy AE, El-Husseini AA, El-Sayed M et al (2005) A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 67:2039–2045. https://doi.org/10.1111/j.1523-1755.2005.00306.x

    Article  PubMed  Google Scholar 

  27. Nowacka-Cieciura E, Cieciura T, Bączkowska T, Kozińska-Przybył O, Tronina O, Chudziński W, Pacholczyk M, Durlik M (2006) Bisphosphonates are effective prophylactic of early bone loss after renal transplantation. Transplant Proc 38:165–167. https://doi.org/10.1016/j.transproceed.2005.12.041

    Article  CAS  PubMed  Google Scholar 

  28. Conley E, Muth B, Samaniego M, Lotfi M, Voss B, Armbrust M, Pirsch J, Djamali A (2008) Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation 86:231–237. https://doi.org/10.1097/TP.0b013e318176b40f

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Torregrosa JV, Fuster D, Pedroso S, Diekmann F, Campistol JM, Rubí S, Oppenheimer F (2007) Weekly risedronate in kidney transplant patients with osteopenia. Transpl Int 20:708–711. https://doi.org/10.1111/j.1432-2277.2007.00501.x

    Article  CAS  PubMed  Google Scholar 

  30. Stein EM, Ortiz D, Jin Z, McMahon DJ et al (2011) Prevention of fractures after solid organ transplantation: a meta-analysis. J Clin Endocrinol Metab 96:3457–3465. https://doi.org/10.1210/jc.2011-1448

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Versele EB, Van Laecke S, Dhondt AW et al (2016) Bisphosphonates for preventing bone disease in kidney transplant recipients: a meta-analysis of randomized controlled trials. Transpl Int 29:153–164. https://doi.org/10.1111/tri.12691

    Article  CAS  PubMed  Google Scholar 

  32. Marcén R, Caballero C, Uriol O, Fernández A, Villafruela JJ, Pascual J, Martins J, Rodriguez N, Burgos FJ, Ortuño J (2007) Prevalence of osteoporosis, osteopenia, and vertebral fractures in long-term renal transplant recipients. Transplant Proc 39:2256–2258. https://doi.org/10.1016/j.transproceed.2007.07.073

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de médecine interne, CH Armentières, F-59280, Armentières, France

    N. Segaud

  2. Service de Rhumatologie, CHU Lille, F-59000, Lille, France

    N. Segaud, I. Legroux & B. Cortet

  3. EA 4490 - PMOI - Physiopathologie des Maladies Osseuses Inflammatoires, Université de Lille, F-59000, Lille, France

    I. Legroux & B. Cortet

  4. Service de Néphrologie, CHU Lille, F-59000, Lille, France

    M. Hazzan & C. Noel

Authors
  1. N. Segaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Legroux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Hazzan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Noel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Cortet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Segaud.

Ethics declarations

Conflict of interest

Nicolas SEGAUD: none.

Isabelle LEGROUX: none.

Marc HAZZAN has received honorarium and grants from Novartis, Astellas and Roche.

Christian NOEL: none.

Bernard CORTET has received consultancy fees, lecture fees and honorarium from Amgen, Eli Lilly, Expanscience, Ferring, Medtronic, Novartis, Roche Diagnostics and Servier.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Segaud, N., Legroux, I., Hazzan, M. et al. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort. Osteoporos Int 29, 1165–1175 (2018). https://doi.org/10.1007/s00198-018-4383-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-018-4383-2

Keywords

Search

Navigation